AT

An2 Therapeutics

www.an2therapeutics.com link_icon

AN2 Therapeutics, Inc. - Company Research Report



Company Overview



  • Name: AN2 Therapeutics, Inc.

  • Mission: AN2 Therapeutics is committed to improving global human health by discovering and developing novel small molecule therapeutics through their boron chemistry platform. The company aims to address high unmet medical needs in infectious diseases and oncology.

  • Founding Information: Specific founding date not provided. Key founders include Eric Easom, Joseph S. Zakrzewski, George H. Talbot, M.D., FACP, FIDSA, and Michael R.K. (Dickon) Alley, Ph.D.

  • Key People:

  • Eric Easom - Co-Founder, President & CEO, Chair of the Board of Directors

  • Sanjay Chanda, Ph.D. - Chief Development Officer

  • Lucy O. Day - Chief Financial Officer

  • Josh Eizen - Chief Legal Officer and Secretary

  • Headquarters: Located at 1800 El Camino Real, Suite D, Menlo Park, CA 94027.

  • Number of Employees: No information is available.

  • Revenue: No information is available.

  • Known For: AN2 Therapeutics is known for its boron-based chemistry platform intended to develop therapeutics for infectious diseases such as Chagas disease, non-tuberculous mycobacteria (NTM), and melioidosis.


Products



AN2-502998 (Oral)


  • Therapeutic Area: Chagas disease

  • Description: A boron-based small molecule therapeutic candidate targeting chronic Trypanosoma cruzi (T. cruzi) infection. It has shown potential curative activity in preclinical studies across multiple species including non-human primates.

  • Key Features:

  • Exhibits curative activity in preclinical models.

  • Specifically designed to target T. cruzi, addressing a high unmet need in chronic disease treatment.


Epetraborole


  • Therapeutic Areas: Non-tuberculous mycobacterial (NTM) lung disease, melioidosis

  • Description: A boron-containing, orally-available, small molecule inhibitor of the bacterial leucyl-tRNA synthetase enzyme, leading to a novel mechanism of action in blocking protein synthesis.

  • Key Features:

  • Potent activity against Mycobacterium avium complex (MAC) and Mycobacterium abscessus in preclinical models.

  • Potential first-line therapy for NTM lung diseases like M. abscessus.

  • Currently in clinical trials for melioidosis, aiming to reduce its high mortality rate.


Recent Developments



  • New Products Launched: No information is available.

  • New Features Added: No specific features added to existing products are mentioned.

  • New Partnerships: AN2 Therapeutics has a strategic partnership with Brii Biosciences, which has licensed rights to develop, manufacture, and commercialize certain compounds, including epetraborole, in China, Hong Kong, Taiwan, and Macau.


Clinical Trials


  • Melioidosis: A Phase 2 study of epetraborole in acute melioidosis is planned to commence in mid-2025.

  • NTM Lung Disease: The company continues to explore epetraborole's potential in treatment-naive MAC lung disease despite challenges in treatment-refractory cases.


Research and Publications


  • Several studies have been published on epetraborole's efficacy in murine models of Mycobacterium abcessus lung infection, evaluation of in vitro drug-drug interaction potential, and exploring its activity against Burkholderia pseudomallei as a promising treatment for melioidosis.


Note: The report leverages available information, and any missing elements such as employee count or revenue are marked as "No information is available".